Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|180|5|666-679

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.180, Iss.5, 2018-03, pp. : 666-679

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 43, Iss. 1, 2018-02 ,pp. : 145-149

John Wiley & Sons Inc

Access to resources Recommend Favorite

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 125-128

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 5, 2015-09 ,pp. : 734-736

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 4, 2015-08 ,pp. : 445-456

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab Therapy in Cutaneous Infiltration of Chronic Lymphocytic Leukaemia

By  

Acta Haematologica, Vol. 130, Iss. 1, 2013-02 ,pp. : 47-51

Karger

Access to resources Recommend Favorite